Thrombin Activatable Fibrinolysis Inhibitor: A Putative Target to Enhance Fibrinolysis

Abstract

Thrombin activatable fibrinolysis inhibitor (TAFI) was discovered two decades ago consequent to the identification of an unstable carboxypeptidase (CPU) formed upon thrombin activation of its proenzyme. The antifibrinolytic effects of the activated form (TAFIa, CPU) are linked with its capacity to remove C-terminal lysines from the surface of the fibrin clot. A distinctive characteristic of TAFIa is its temperature-dependent conformational instability: TAFIa activity spontaneously decays with an apparent half-life of 8 to 15 minutes at 37°C. A variety of studies has demonstrated a role for TAFI/TAFIa in venous and arterial diseases. In addition, a role for TAFI/TAFIa in inflammation and cell migration has also been shown. Because TAFI/TAFIa is a potential risk factor for thrombotic disorders, many inhibitors, both at the level of activation or at the level of activity, have been developed and were proven to exhibit a profibrinolytic effect in animal models. Pharmacologically active inhibitors of the TAFI/TAFIa system may open new ways for the prevention of thrombotic diseases or for the establishment of adjunctive treatments during thrombolytic therapy.

Keywords

thrombin activatable fibrinolysis inhibitor - TAFI - proCPU - fibrinolysis

• References

• 1 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biochem 1995; 270: 14477-14484
• 2 Hendriks D, Scharpé S, van Sande M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27 (5) 277-285
• 3 Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162 (3) 933-939
• 4 Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266 (32) 21833-21838
• 5 Vanhoof G, Wauters J, Schatteman K , et al. The gene for human carboxypeptidase U (CPU)—a proposed novel regulator of plasminogen activation maps to 13q14.11. Genomics 1996; 38 (3) 454-455
• 6 Boffa MB, Reid TS, Joo E, Nesheim ME, Koschinsky ML. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry 1999; 38 (20) 6547-6558
• 7 Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 2007; 40 (7) 431-442
• 8 Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JCM, Bouma BN. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101 (12) 4844-4846
• 9 Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88 (6) 2093-2100
• 10 Mosnier LO, von dem Borne PAK, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80 (5) 829-835
• 11 Gils A, Alessi MC, Brouwers E , et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23 (6) 1122-1127
• 12 Boffa MB, Maret D, Hamill JD , et al. Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis. Blood 2008; 111 (1) 183-189
• 13 Valnickova Z, Christensen T, Skottrup P, Thøgersen IB, Højrup P, Enghild JJ. Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation. Biochemistry 2006; 45 (5) 1525-1535
• 14 Marx PF, Brondijk THC, Plug T , et al. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation. Blood 2008; 112 (7) 2803-2809
• 15 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271 (28) 16603-16608
• 16 Mao SS, Cooper CM, Wood T, Shafer JA, Gardell SJ. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J Biol Chem 1999; 274 (49) 35046-35052
• 17 Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273 (4) 2127-2135
• 18 Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Il-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biochem 2002; 277: 1021-1030
• 19 Ceresa E, Peeters M, Declerck PJ, Gils A. Announcing a TAFIa mutant with a 180-fold increased half-life and concomitantly a strongly increased antifibrinolytic potential. J Thromb Haemost 2007; 5 (2) 418-420
• 20 Knecht W, Willemse J, Stenhamre H , et al. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis. FEBS J 2006; 273 (4) 778-792
• 21 Boffa MB, Bell R, Stevens WK, Nesheim ME. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000; 275 (17) 12868-12878
• 22 Leurs J, Wissing BM, Nerme V, Schatteman K, Björquist P, Hendriks D. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thromb Haemost 2003; 89 (2) 264-271
• 23 Vercauteren E, Emmerechts J, Peeters M, Hoylaerts MF, Declerck PJ, Gils A. Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model. Blood 2011; 117 (17) 4615-4622
• 24 Mishra N, Vercauteren E, Develter J, Bammens R, Declerck PJ, Gils A. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms. Thromb Haemost 2011; 106 (1) 90-101
• 25 Vercauteren E, Mutch NJ, Declerck PJ, Gils A. Plasmin and the thrombin-thrombomodulin complex both contribute to TAFI activation in whole blood model thrombi. J Thromb Haemost 2012; ; In press
• 26 Binette TM, Taylor Jr FB, Peer G, Bajzar L. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood 2007; 110 (9) 3168-3175
• 27 Willemse JL, Polla M, Hendriks DF. The intrinsic enzymatic activity of plasma procarboxypeptidase U (TAFI) can interfere with plasma carboxypeptidase N assays. Anal Biochem 2006; 356 (1) 157-159
• 28 Valnickova Z, Thøgersen IB, Potempa J, Enghild JJ. Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase. J Biol Chem 2007; 282 (5) 3066-3076
• 29 Leurs J, Hendriks D. Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 2005; 94 (3) 471-487
• 30 Leurs J, Nerme V, Sim Y, Hendriks D, Carboxypeptidase U. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J Thromb Haemost 2004; 2 (3) 416-423
• 31 Walker JB, Bajzar L. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability. J Biol Chem 2004; 279 (27) 27896-27904
• 32 Willemse JL, Heylen E, Hendriks DF. The intrinsic enzymatic activity of procarboxypeptidase U (TAFI) does not significantly influence the fibrinolysis rate: a rebuttal. J Thromb Haemost 2007; 5 (6) 1334-1336
• 33 Valnickova Z, Thøgersen IB, Potempa J, Enghild JJ. The intrinsic enzymatic activity of procarboxypeptidase U (TAFI) does not significantly influence the fibrinolytic rate: reply to a rebuttal. J Thromb Haemost 2007; 5 (6) 1336-1337
• 34 Foley JH, Kim P, Nesheim ME. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis. J Biol Chem 2008; 283 (14) 8863-8867
• 35 Mishra N, Buelens K, Theyskens S, Compernolle G, Gils A, Declerck PJ. Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis. J Thromb Haemost 2012; 10 (6) 1091-1099
• 36 Shinohara T, Sakurada C, Suzuki T , et al. Pro-carboxypeptidase R cleaves bradykinin following activation. Int Arch Allergy Immunol 1994; 103 (4) 400-404
• 37 Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002; 46 (2) 131-134
• 38 Myles T, Leung LLK. Thrombin hydrolysis of human osteopontin is dependent on thrombin anion-binding exosites. J Biol Chem 2008; 283 (26) 17789-17796
• 39 Du X-Y, Zabel BA, Myles T , et al. Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. J Biol Chem 2009; 284 (2) 751-758
• 40 Leung LLK, Myles T, Nishimura T, Song JJ, Robinson WH. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Mol Immunol 2008; 45 (16) 4080-4083
• 41 Myles T, Nishimura T, Yun TH , et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278 (51) 51059-51067
• 42 Nagashima M, Yin ZF, Zhao L , et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109 (1) 101-110
• 43 te Velde EA, Wagenaar GTM, Reijerkerk A , et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 1 (10) 2087-2096
• 44 Guimarães AHC, Laurens N, Weijers EM, Koolwijk P, van Hinsbergh VWM, Rijken DC. TAFI and pancreatic carboxypeptidase B modulate in vitro capillary tube formation by human microvascular endothelial cells. Arterioscler Thromb Vasc Biol 2007; 27 (10) 2157-2162
• 45 Willemse JL, Heylen E, Nesheim ME, Hendriks DF. Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?. J Thromb Haemost 2009; 7 (12) 1962-1971
• 46 Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96 (5) 2534-2538
• 47 Reverter D, Vendrell J, Canals F , et al. A carboxypeptidase inhibitor from the medical leech Hirudo medicinalis. Isolation, sequence analysis, cDNA cloning, recombinant expression, and characterization. J Biol Chem 1998; 273 (49) 32927-32933
• 48 Arolas JL, Lorenzo J, Rovira A, Castellà J, Aviles FX, Sommerhoff CP. A carboxypeptidase inhibitor from the tick Rhipicephalus bursa: isolation, cDNA cloning, recombinant expression, and characterization. J Biol Chem 2005; 280 (5) 3441-3448
• 49 Gils A, Ceresa E, Macovei AM , et al. Modulation of TAFI function through different pathways—implications for the development of TAFI inhibitors. J Thromb Haemost 2005; 3 (12) 2745-2753
• 50 Hillmayer K, Vancraenenbroeck R, De Maeyer M, Compernolle G, Declerck PJ, Gils A. Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor. J Thromb Haemost 2008; 6 (11) 1892-1899
• 51 Hendrickx MLV, DE Winter A, Buelens K , et al. TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation. J Thromb Haemost 2011; 9 (11) 2268-2277
• 52 Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999; 94 (8) 2735-2743
• 53 Buelens K, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck PJ. Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor. J Thromb Haemost 2010; 8 (6) 1302-1312
• 54 Schneider M, Nesheim M. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis. J Thromb Haemost 2003; 1 (1) 147-154
• 55 Vercauteren E, Gils A. Is there any need for a TAFI(a) inhibitor as thrombolytic drug?. Thromb Res 2012; 130 (4) 574-575
• 56 Heylen E, Willemse J, Hendriks D. An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis. Front Biosci 2011; 16: 2427-2450
• 57 Ladenvall C, Gils A, Jood K, Blomstrand C, Declerck PJ, Jern C. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol 2007; 27 (4) 955-962
• 58 Brouns R, Heylen E, Willemse JL , et al. The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome. J Thromb Haemost 2010; 8 (1) 75-80
• 59 Jood K, Redfors P, Gils A, Blomstrand C, Declerck PJ, Jern C. Convalescent plasma levels of TAFI activation peptide predict death and recurrent vascular events in ischemic stroke survivors. J Thromb Haemost 2012; 10 (4) 725-727
• 60 de Bruijne ELE, Gils A, Rijken DC , et al. High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease. Thromb Res 2011; 127 (3) 254-258
• 61 Meltzer ME, Lisman T, de Groot PG , et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116 (1) 113-121
• 62 de Bruijne ELE, Gils A, Guimarães AHC , et al. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study. J Thromb Haemost 2009; 7 (6) 919-927
• 63 Tregouet DA, Schnabel R, Alessi MC , et al; AtheroGene Investigators. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2009; 7 (1) 49-57
• 64 Schatteman KA, Goossens FJ, Scharpé SS, Hendriks DF. Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis. Thromb Haemost 1999; 82 (6) 1718-1721
• 65 Kim PYG, Kim PY, Hoogendorn H, Giles AR, Nesheim ME. Activated thrombin-activatable fibrinolysis inhibitor is generated in vivo at levels that can substantially affect fibrinolysis in chimpanzees in response to thrombin generation. J Thromb Haemost 2008; 6 (9) 1600-1602
• 66 Marx PF, Wagenaar GTM, Reijerkerk A , et al. Characterization of mouse thrombin-activatable fibrinolysis inhibitor. Thromb Haemost 2000; 83 (2) 297-303
• 67 Hillmayer K, Macovei A, Pauwels D, Compernolle G, Declerck PJ, Gils A. Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI)—a comparative study assessing the biological equivalence of rat, murine and human TAFI. J Thromb Haemost 2006; 4 (11) 2470-2477
• 68 Morser J, Gabazza EC, Myles T, Leung LLK. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?. J Thromb Haemost 2010; 8 (5) 868-876
• 69 Mao SS, Holahan MA, Bailey C , et al. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice. Blood Coagul Fibrinolysis 2005; 16 (6) 407-415
• 70 Wang XK, Smith PL, Hsu MY, Tamasi JA, Bird E, Schumacher WA. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis. J Thromb Thrombolysis 2007; 23 (1) 41-49
• 71 Vercauteren E, Peeters M, Hoylaerts MF , et al. The hyperfibrinolytic state of mice with combined TAFI and PAI-1 gene deficiency is critically dependent on TAFI deficiency. J Thromb Haemost 2012; 10 (12) 2555-2562
• 72 Kraft P, Schwarz T, Meijers JCM, Stoll G, Kleinschnitz C. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke. PLoS ONE 2010; 5 (7) e11658
• 73 Orbe J, Rodriguez JA, Orset C , et al. MMP-10 as a new profibrinolytic agent in experimental stroke through TAFI-mediated mechanism. J Thromb Haemost 2012; 10: E11-E12
• 74 Nagashima M, Werner M, Wang M , et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000; 98 (4) 333-342
• 75 Wang YX, da Cunha V, Vincelette J , et al. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost 2007; 97 (1) 54-61
• 76 Minnema MC, Friederich PW, Levi M , et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101 (1) 10-14
• 77 Muto Y, Suzuki K, Sato E, Ishii H. Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats. Eur J Pharmacol 2003; 461 (2-3) 181-189
• 78 Suzuki K, Muto Y, Fushihara K , et al. Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B. J Pharmacol Exp Ther 2004; 309 (2) 607-615
• 79 Muto Y, Suzuki K, Iida H , et al. EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats. Crit Care Med 2009; 37 (5) 1744-1749
• 80 Hashimoto M, Yamashita T, Oiwa K, Watanabe S, Giddings JC, Yamamoto J. Enhancement of endogenous plasminogen activator-induced thrombolysis by argatroban and APC and its control by TAFI, measured in an arterial thrombolysis model in vivo using rat mesenteric arterioles. Thromb Haemost 2002; 87 (1) 110-113
• 81 Wang X, Smith PL, Hsu MY, Ogletree ML, Schumacher WA. Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor. J Thromb Haemost 2006; 4 (2) 403-410
• 82 Sasaki T, Yoshimoto N, Sugimoto K , et al. Intravenous and oral administrations of DD2 [7-Amino-2-(sulfanylmethyl)heptanoic acid] produce thrombolysis through inhibition of plasma TAFIa in rats with tissue factor-induced microthrombosis. Thromb Res 2012; 130 (4) e222-e228
• 83 Antovic J, Schulman S, Eelde A, Blombäck M. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A. Haemophilia 2001; 7 (6) 557-560
• 84 Foley JH, Nesheim ME, Rivard GE, Brummel-Ziedins KE. Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A. Haemophilia 2012; 18 (3) e316-e322
• 85 Broze Jr GJ, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88 (10) 3815-3823
• 86 Mosnier LO, Lisman T, van den Berg HM, Nieuwenhuis HK, Meijers JCM, Bouma BN. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001; 86 (4) 1035-1039
• 87 Foley JH, Petersen KU, Rea CJ , et al. Solulin increases clot stability in whole blood from humans and dogs with hemophilia. Blood 2012; 119 (15) 3622-3628
• 88 Abshire T. TAFI made stickier. Blood 2012; 119 (15) 3380-3381
• 89 Garand M, Lin JHH, Hill CE, Zagorac B, Koschinsky ML, Boffa MB. Regulation of the mouse gene encoding TAFI by TNFα: role of NFκB binding site. Cytokine 2012; 57 (3) 389-397
• 90 Owczarek D, Undas A, Foley JH, Nesheim ME, Jabłonski K, Mach T. Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD. J Crohn's Colitis 2012; 6 (1) 13-20
• 91 Sayilir A, Beyazit Y, Yesil Y , et al. Plasma thrombin-activatable fibrinolysis inhibitor as an indicator of inflammation and disease severity in acute pancreatitis. Clin Res Hepatol Gastroenterol 2012; 36 (5) 498-504
• 92 Asai S, Sato T, Tada T , et al. Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice. J Immunol 2004; 173 (7) 4669-4674
• 93 Nishimura T, Myles T, Piliponsky AM, Kao PN, Berry GJ, Leung LLK. Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo. Blood 2007; 109 (5) 1992-1997
• 94 Song JJ, Hwang I, Cho KH , et al; Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis (CLEAR) Registry. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest 2011; 121 (9) 3517-3527
• 95 Renckens R, Roelofs JJ, ter Horst SAJ , et al. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol 2005; 175 (10) 6764-6771
• 96 Kim PY, Kim PY, Taylor Jr FB, Nesheim ME. Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis. J Thromb Thrombolysis 2012; 33 (4) 412-415
• 97 Małyszko J, Tymcio J. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension. Pol Arch Med Wewn 2008; 118 (1-2) 36-41
• 98 Hori Y, Gabazza EC, Yano Y , et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87 (2) 660-665
• 99 Kitagawa N, Yano Y, Gabazza EC , et al. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients. Diabetes Res Clin Pract 2006; 73 (2) 150-157
• 100 Yano Y, Kitagawa N, Gabazza EC , et al. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab 2003; 88 (2) 736-741
• 101 Verkleij CJN, Roelofs JJTH, Havik SR, Meijers JCM, Marx PF. The role of thrombin-activatable fibrinolysis inhibitor in diabetic wound healing. Thromb Res 2010; 126 (5) 442-446